Leveraging Evolving Data to Inform Treatment in HR-Positive, HER2-Negative Advanced Breast Cancer

Watch the interactive on-demand CME/MOC-certified Webcast and download the slides from a CCO symposium at SABCS 2019 to get up to date on the latest clinical data informing optimal treatment of HR+/HER2- MBC, including expert discussion of patient cases and a look ahead at promising agents in the setting of endocrine therapy–pretreated disease that may soon change practice.
Joyce O'Shaughnessy, MD
Program Director
Hope S. Rugo, MD
Eric P. Winer, MD

On-Demand Webcast

In this CME/MOC-certified, on-demand Webcast of a CCO symposium at SABCS 2019, a panel of experts review and discuss evolving strategies for treating HR-positive, HER2-negative advanced breast cancer.

Joyce O'Shaughnessy, MD
Program Director
Hope S. Rugo, MD Eric P. Winer, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits US Physicians: maximum of 1.75 Medical Knowledge MOC point(s) Released: January 21, 2020 Expired: January 20, 2021

Downloadable Slidesets

Download this slideset to explore future directions in the treatment of HR+/HER2- metastatic breast cancer, including a review of novel agents in the setting of resistance to standard-of-care therapies.

Joyce O'Shaughnessy, MD
Program Director
Released: December 11, 2019

Download this slideset to review the latest clinical data on the evolving role of mTOR and PIK3 inhibitors in the treatment of HR+/HER2- metastatic breast cancer.

Hope S. Rugo, MD Released: December 11, 2019

Download this slideset to review the latest clinical data informing optimal use of CDK4/6 inhibitors in the treatment of HR+/HER2- metastatic breast cancer, including an overview of resistance to these agents.

Eric P. Winer, MD Released: December 11, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Immunomedics, Inc.
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?